Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type j% `* ^. T/ o L9 X+ r6 G
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 & [' r+ r- c0 a, p5 N* s' ~0 J1 [" D
+ Author Affiliations
+ c. C; d! Z9 z! c/ r
" z# ?" r4 w+ Y9 `4 G1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
, }) b6 y% K) N. }$ F# N7 @7 ~5 r2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
+ W" l& t+ |' Q& {0 f6 [; }8 J$ f3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
# }4 l2 ~& ?! s7 @4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan 2 W0 O! T' q Q. c8 g
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
2 l" d1 b9 S0 i; U6 E3 l6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan * q9 z' d1 W5 _9 `& ]
7Kinki University School of Medicine, Osaka 589-8511, Japan , N$ s0 `! {3 L! P2 @" d# _
8Izumi Municipal Hospital, Osaka 594-0071, Japan : e5 f9 h. ]- L7 d$ n0 x+ a- [ q8 q! _
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan O& u7 a, j" d$ |+ g3 }& j; C
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp 2 W3 \% P* r1 F, F$ |, c7 N
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. 0 H6 \2 _; e( I! ^( i1 \
/ |7 G/ H6 P9 t9 s
|